Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (192${count})

  • Therapeutic Pipeline Program, 2016
    Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia

    Study Rationale:                             
    Up to 80% of individuals with Parkinson’s develop Parkinson’s disease dementia (PDD), which is characterized by a progressive loss of memory and a decline...

  • Therapeutic Pipeline Program, 2022
    Evaluating the Efficacy of a mGluR5 Modulator in Preclinical Models of Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is one of many neurodegenerative diseases that are characterized by the buildup of misfolded protein aggregates in the brain. Preclinical data suggest that...

  • Clinical Discovery Awards, 2005
    Executive, ADL, and Cholinergic Functions in PD

    Parkinson's disease is a disorder that is most known for motor impairments of tremor, slowness in moving, and loss of balance. Patients with Parkinson's disease also suffer from non-motor symptoms...

  • Therapeutic Pipeline Program, 2018
    Development of ALK4290 as a Novel Parkinson's Therapeutic

    Study Rationale:
    There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune...

  • 2022: Accelerated Therapeutics Program, 2024
    (SUPPLEMENT) Innovative Therapies for Parkinson’s Disease Through a Novel, Unexploited Gene Expression Mechanism Rooted in Human Genetics Enabling a Precision-medicine Approach

    Study Rationale: Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders caused by an accumulation of protein aggregates that leads to cell death. Genetic studies suggest...

  • Clinical Intervention Awards, 2012
    A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson’s Disease
    Objective/Rationale: In the twenty-first century the motor symptoms of Parkinson’s disease (PD) are typically well-managed. The neurocognitive symptoms of Parkinson’s disease often result in...
Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.